Filtered By:
Therapy: Immunotherapy
Vaccination: Influenza Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul.ABSTRACTBACKGROUND: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration.METHODS: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020. The trial's pri...
Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Melissa Bersanelli Elena Verzoni Alessio Cortellini Raffaele Giusti Lorenzo Calvetti Paola Ermacora Marilena Di Napoli Annamaria Catino Valentina Guadalupi Giorgia Guaitoli Vieri Scotti Francesca Mazzoni Antonello Veccia Pamela Francesca Guglielmini Fabia Source Type: research

Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research

Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction
This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.PMID:37099943 | DOI:10.1016/j.intimp.2023.110210
Source: International Immunopharmacology - April 26, 2023 Category: Allergy & Immunology Authors: Jonaid Ahmad Malik Javed N Agrewala Source Type: research

Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules. MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/ Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials
Front Immunol. 2022 Sep 23;13:999704. doi: 10.3389/fimmu.2022.999704. eCollection 2022.ABSTRACTSystemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that frequently affects the kidneys, known as lupus nephritis (LN). Such patients are treated with antimalarials, corticosteroids or immunosuppressive drugs, and more recently, target-specific biological drugs. Although efficacy of these therapies improved SLE-related outcomes, SLE remains associated with higher rates of infections. Here, we performed a comprehensive systemic review of infectious complications in clinical trials covering drug interventions f...
Source: Herpes - October 10, 2022 Category: Infectious Diseases Authors: Stefanie Steiger Louisa Ehreiser Juliane Anders Hans-Joachim Anders Source Type: research

Fight Aging! Newsletter, September 19th 2022
Conclusion Use of the Khavinson peptides and melatonin in combination in this way, at this dose, negatively impacts the thymus, producing a reduction in active tissue and increase in atrophy to fatty tissue. The degree to which this atrophy occurred is greater than one would expect to take place over nine months of aging at this stage of life. Why did this outcome occur, given the animal studies showing thymic regrowth, and the studies showing reduced later life mortality following use of thymogen? We can only speculate. Firstly, the dose makes the poison, and the dosing here may have been too high, too frequ...
Source: Fight Aging! - September 18, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
The safety and efficacy of influenza vaccination is not well-studied in cancer patients receiving immune checkpoint inhibitors (ICIs). A systematic review and meta-analysis was performed aiming to summarize available data regarding influenza vaccination in ICI-treated cancer patients. Peer-reviewed studies or nonpeer-reviewed conference abstracts including ICI-treated cancer patients who received at least 1 dose of influenza vaccine were deemed eligible. A systematic search in PubMed/EMBASE was performed until October 26, 2021. Endpoints of interest included mortality as the primary outcome and secondary safety outcomes su...
Source: Journal of Immunotherapy - June 19, 2022 Category: Allergy & Immunology Tags: Clinical Studies Source Type: research

CD4 < sup > + < /sup > T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
CONCLUSION: CD4+ T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific TH1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.PMID:35580929 | DOI:10.1136/jitc-2021-004022
Source: Cancer Control - May 17, 2022 Category: Cancer & Oncology Authors: Minglu Xiao Luoyingzi Xie Guoshuai Cao Shun Lei Pengcheng Wang Zhengping Wei Yuan Luo Jingyi Fang Xingxing Yang Qizhao Huang Lifan Xu Junyi Guo Shuqiong Wen Zhiming Wang Qing Wu Jianfang Tang Lisha Wang Xiangyu Chen Cheng Chen Yanyan Zhang Wei Yao Jianqia Source Type: research

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
AbstractThe COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lil...
Source: BioDrugs - April 27, 2022 Category: Drugs & Pharmacology Source Type: research

Fight Aging! Newsletter, January 3rd 2022
In this study, we showed that the iPaD (inducing Plagl2 and anti-Dyrk1a) lentivirus substantially rejuvenated the proliferative and neurogenic potential of NSCs in the aged brain. Clonal analysis by a sparse labeling approach as well as transcriptome analysis indicated that iPaD can rejuvenate aged NSCs (19-21 mo of age) to a level comparable with those at 1 or 2 months of age and successfully improved cognition of aged mice. Once rejuvenated and activated by iPaD, aged dormant NSCs can generate, on average, 4.9 neurons but very few astrocytes in 3-week tracing. Furthermore, these activated NSCs were maintained for ...
Source: Fight Aging! - January 2, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, August 30th 2021
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out mo...
Source: Fight Aging! - August 29, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs